Premium
The comparison between intradermal injection of abobotulinumtoxinA and normal saline for face‐lifting: a split‐face randomized controlled trial
Author(s) -
Wanitphakdeedecha Rungsima,
Ungaksornpairote Chanida,
Kaewkes Arisa,
Rojanavanich Viboon,
Phothong Weeranut,
Manuskiatti Woraphong
Publication year - 2016
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.12289
Subject(s) - medicine , hemifacial spasm , trigeminal neuralgia , eyelash , randomized controlled trial , saline , botulinum toxin , glabella , surgery , anesthesia , forehead , facial nerve , genetics , biology
Summary Background Botulinum toxin type A ( BTA ) has been approved for the treatment of strabismus, blepharospasm, muscle spasm, cervical dystonia, pain syndrome, glabella wrinkles, and severe primary axillary hyperhidrosis. Intradermal injection of BTA has been used off‐label by many clinicians for the purpose of face‐lifting effect. Few studies on onabotulinumtoxinA ( ONA ) demonstrated no clinical efficacy on face‐lifting effect when comparing to normal saline solution ( NSS ). So far, there is no split‐face comparison study on face‐lifting effect of abobotulinumtoxinA ( ABO ). Objective To determine the face‐lifting effect of ABO intradermal injection and NSS . Methods Twenty‐two subjects with symmetrical faces on both facial expression and expressionless were randomly injected with ABO at 1:7 cc dilution (500 unit or one vial in 7 cc of NSS ) on one side and NSS on the other side using intradermal injection technique. Standardized photographic documentation was obtained at baseline, and at 2 weeks after treatment. The face‐lifting effect was graded by two blinded dermatologists using photographic comparison and rated by the patients. Side effects were also recorded at the end of the study. Results Face‐lifting effect was demonstrated in 40.9% and 4.5% of patients with ABO and NSS , respectively. There was a statistically significant difference in face‐lifting effect when comparing between ABO and NSS ( P = 0.021). The face‐lifting was reported in 50.0% of patients receiving ABO injection. The patients with oval‐face shape tended to respond better with ABO ( P = 0.046). The odd of face‐lifting effect for patients aged younger than 32 was higher than patients aged older than 32 with the odds ratio of 7.9 and 95% confidence interval of 1.1–56.1. Facial asymmetry was found in 22.7% of subjects. Conclusions This study demonstrated the face‐lifting effect of ABO intradermal injection. Patients with oval‐face shape and aged younger than 32 tended to respond better. Therefore, patient selection should be emphasized to improve efficacy of this technique.